Michael Benkowitz Sells 15,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR) COO Michael Benkowitz sold 15,000 shares of United Therapeutics stock in a transaction on Monday, November 11th. The shares were sold at an average price of $407.32, for a total transaction of $6,109,800.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Michael Benkowitz also recently made the following trade(s):

• On Thursday, November 7th, Michael Benkowitz sold 15,000 shares of United Therapeutics stock. The shares were sold at an average price of $401.44, for a total transaction of $6,021,600.00.
• On Friday, November 1st, Michael Benkowitz sold 14,700 shares of United Therapeutics stock. The stock was sold at an average price of $374.46, for a total transaction of $5,504,562.00.

United Therapeutics Trading Down 0.1 %

Shares of UTHR stock opened at $400.45 on Thursday. The stock has a market cap of $17.88 billion, a price-to-earnings ratio of 17.59, a PEG ratio of 1.17 and a beta of 0.56. The stock has a 50-day moving average of $361.85 and a 200-day moving average of $326.24. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $417.82.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. During the same quarter last year, the company earned $5.38 earnings per share. The company’s revenue for the quarter was up 22.9% on a year-over-year basis. Sell-side analysts forecast that United Therapeutics Co. will post 25.1 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. LADENBURG THALM/SH SH boosted their price target on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a report on Thursday, October 31st. HC Wainwright upped their price target on shares of United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Jefferies Financial Group lifted their price target on United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. Argus upped their price target on United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Finally, Oppenheimer upped their target price on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $370.86.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of UTHR. CreativeOne Wealth LLC purchased a new position in shares of United Therapeutics during the 3rd quarter worth approximately $215,000. Glenmede Trust Co. NA raised its holdings in United Therapeutics by 6.4% in the 3rd quarter. Glenmede Trust Co. NA now owns 68,605 shares of the biotechnology company’s stock worth $24,585,000 after purchasing an additional 4,145 shares during the period. Bridgewater Associates LP increased its stake in United Therapeutics by 384.3% in the 3rd quarter. Bridgewater Associates LP now owns 61,755 shares of the biotechnology company’s stock worth $22,130,000 after buying an additional 49,003 shares in the last quarter. Townsquare Capital LLC purchased a new stake in United Therapeutics in the 3rd quarter worth $426,000. Finally, Brooklyn Investment Group purchased a new position in shares of United Therapeutics during the third quarter valued at about $33,000. Institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.